(Reuters) – European regulators have recommended approval of the first medicine containing stem cells to treat a rare condition caused by burns to the eye.
The European Medicines Agency said on Friday that Holoclar, from privately held Italian company Chiesi, had been given a green light for moderate to severe limbal stem cell deficiency due to physical or chemical burns. Left untreated, the condition can result in blindness.